TY - JOUR
T1 - Veno-occlusive disease of the liver after blood and marrow transplantation
T2 - Analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator
AU - Litzow, Mark R.
AU - Repoussis, Panagiotis D.
AU - Schroeder, Georgene
AU - Schembri-Wismayer, David
AU - Batts, Kenneth P.
AU - Anderson, Peter M.
AU - Arndt, Carola A.S.
AU - Chen, Michael G.
AU - Gastineau, Dennis A.
AU - Gertz, Morie A.
AU - Inwards, David J.
AU - Lacy, Martha Q.
AU - Tefferi, Ayalew
AU - Noël, Pierre
AU - Solberg, Lawrence A.
AU - Letendre, Louis
AU - Hoagland, H. Clark
PY - 2002/11/1
Y1 - 2002/11/1
N2 - We reviewed our blood and marrow transplantation (BMT) database from April 1982 to July 1996 and identified 111 of 474 patients with serum bilirubin concentration (SBR) ≥ 34 μmol/l for two onsecutive days within the first 20 days after related allogeneic or autologous BMT. Of the 111, 73 fulfilled the Seattle criteria for veno-occlusive disease of the liver (VOD) and had no other obvious cause for liver dysfunction. The patients were 16-60 years old (median, 39 years), and 41 were male (56%). Fourteen patients (19%) had autologous BMT, and 59 (81%) had allogeneic BMT. Twenty-eight (38%), 12 (16%), and 33 (45%) patients had severe, moderate, and mild VOD, respectively, by Seattle criteria. None of 23 patients with maximum (max) SBR ≥ 257 μmol/l survived, all patients with max SBR ≤ 128 μmol/l survived, and 7 of 15 patients (47%) with max SBR 128-257 μmol/l survived. The only pre-transplantation risk factor predictive of severe VOD was advanced disease state (P = 0.035), and the only transplant factors that predicted severe VOD were max SBR (P = 0.01) and maximum blood urea level (P = 0.03). Ten patients (all with creatinine levels ≥ 150 μmol/l) were treated with tissue plasminogen activator; only two had a significant response and only one survived beyond day 120.
AB - We reviewed our blood and marrow transplantation (BMT) database from April 1982 to July 1996 and identified 111 of 474 patients with serum bilirubin concentration (SBR) ≥ 34 μmol/l for two onsecutive days within the first 20 days after related allogeneic or autologous BMT. Of the 111, 73 fulfilled the Seattle criteria for veno-occlusive disease of the liver (VOD) and had no other obvious cause for liver dysfunction. The patients were 16-60 years old (median, 39 years), and 41 were male (56%). Fourteen patients (19%) had autologous BMT, and 59 (81%) had allogeneic BMT. Twenty-eight (38%), 12 (16%), and 33 (45%) patients had severe, moderate, and mild VOD, respectively, by Seattle criteria. None of 23 patients with maximum (max) SBR ≥ 257 μmol/l survived, all patients with max SBR ≤ 128 μmol/l survived, and 7 of 15 patients (47%) with max SBR 128-257 μmol/l survived. The only pre-transplantation risk factor predictive of severe VOD was advanced disease state (P = 0.035), and the only transplant factors that predicted severe VOD were max SBR (P = 0.01) and maximum blood urea level (P = 0.03). Ten patients (all with creatinine levels ≥ 150 μmol/l) were treated with tissue plasminogen activator; only two had a significant response and only one survived beyond day 120.
KW - Blood and marrow transplantation
KW - Risk factors
KW - Severity
KW - Tissue plasminogen activator
KW - Veno-occlusive disease
UR - http://www.scopus.com/inward/record.url?scp=0036838232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036838232&partnerID=8YFLogxK
U2 - 10.1080/1042819021000032962
DO - 10.1080/1042819021000032962
M3 - Article
C2 - 12533034
AN - SCOPUS:0036838232
SN - 1042-8194
VL - 43
SP - 2099
EP - 2107
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 11
ER -